Download PDF
Thromb Haemost 1982; 48(02): 166-168
DOI: 10.1055/s-0038-1657248
Original Article
Schattauer GmbH Stuttgart

Effects of Ticlopidine on Platelet Function and Blood Coagulation

F Violi
The IVth Clinica Medica, University of Rome, Rome, Italy
,
C Alessandri
The IVth Clinica Medica, University of Rome, Rome, Italy
,
S Frattaroli
The IVth Clinica Medica, University of Rome, Rome, Italy
,
A Ghiselli
The IVth Clinica Medica, University of Rome, Rome, Italy
,
F Balsano
The IVth Clinica Medica, University of Rome, Rome, Italy
› Author Affiliations
Further Information

Publication History

Received 03 May 1982

Accepted 02 August 1982

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A double blind study was performed on 20 atherosclerotic patients. A placebo was administered to one group of 10 patients (group A) and ticlopidine (500 mg/day) was administered to another group of 10 patients (group B) for one month. ADP and collagen-induced platelet aggregation (PA), platelet malondial-deyde (MDA) produced by thrombin stimulation and plasma beta-thromboglobulin (βTG) levels, prothrombin time, activated partial thromboplastin time (APTT) fibrinogen, antithrombin (AT) III, fibrin(ogen) degradation products, alpha2-antiplasmin and plasminogen were evaluated in both groups before and after treatment. No changes in PA, MDA and βTG were seen in group A. Group B showed a significant decrease of PA, βTG and a significant increase of MDA. No changes on blood coagulation data were seen in either group. This study suggests that ticlopidine is able to inhibit platelet function in vivo.

Keywords

Blood coagulation - Platelet function - Ticlopidine
 

  • References

  • 1 Ashida SI, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in rat. Thromb Haemostas 1979; 41: 436-449
    PubMedGoogle Scholar
  • 2 Thébault JJ, Blatrix CE, Blanchard JF, Panak EH. Effects of ticlopidine, a new platelet aggregation inhibitor. Clin Pharmacol Ther 1975; 18: 485-490
    CrossrefPubMedGoogle Scholar
  • 3 Johnson M, Walton PL, Cotton RC, Strachan CJL. Pharmacological evaluation of ticlopidine, a novel inhibitor of platelet function. Thromb Haemostas 1977; 38: 64 (Abstr.).
    PubMedGoogle Scholar
  • 4 Lagarde M, Ggazi I, Dechavanne M. Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production. Prostaglandins Med 1979; 2: 440-443
    PubMedGoogle Scholar
  • 5 Bonne C, Martin B, Regnault F. Hypothetic mechanism of ticlopidine induced hypersensitivity to PGE1 in rat platelets. Thromb Res 1981; 21: 157-164
    CrossrefPubMedGoogle Scholar
  • 6 Bruno JJ, Yang D, Taylor LA, Feamster C. Role of Platelet cAMP and prostaglandin synthesis in platelet aggregation inhibition by ticlopidine hydrochloride. Thromb Haemostas 1981; 46: 66 (Abstr.).
    PubMedGoogle Scholar
  • 7 Lee M, Paton RC, Ruan C. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. VIII Intern Congr on Thrombosis and Haemostasis, Toronto, July 11-18 1981 (Abstr.).
    PubMedGoogle Scholar
  • 8 O'Brien JR, Etherington MD, Shuttleworth RO. Ticlopidine an antiplatelet drug: effects in human volunteers. Thromb Res 1978; 13: 245-254
    CrossrefPubMedGoogle Scholar
  • 9 Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
    PubMedGoogle Scholar
  • 10 Friberger P, Knor M, Gustavson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
    PubMedGoogle Scholar
  • 11 Bom GVR. Platelet aggregation by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 12 Stuart MJ, Murphy S, Oski FA. A simple nonradioisotope technic for the determination of platelet life-span. N Engl J Med 1975; 292: 1310-1313
    CrossrefPubMedGoogle Scholar
  • 13 Ludlam CA, Cash JD. Studies on the liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
    CrossrefPubMedGoogle Scholar
  • 14 Renner C, Guilmet D, Curtet M. Le ticlopidine en chirurgie cardiaque avec circulation extra-corporelle. Nouv Presse Med 1980; 9: 3249-3251
    PubMedGoogle Scholar
  • 15 Ban I, Shionoya Y, Nekate K, Hirai M, Keway S. A study on the effects of ticlopidine (DE-4160) for suppression of aggregation of platelets and upon the factors of blood coagulation and fibrinolysis and on the results of therapy with it for patients with peripheral vascular diseases. Nippon Rinsho 1978; 55: 2187-2194
    PubMedGoogle Scholar
  • 16 Lecrubier C, Conard J, Samama M, Bousser MG. Essay randomized d'un nouvel agent anti-aggregant le ticlopidine. Therapie 1977; 32: 189
    PubMedGoogle Scholar
  • 17 Steward AMetz. Anti-Inflammatory agents as inhibitors of prostaglandin synthesis in man. Med Clin North Am 1981; 65: 713-757
    CrossrefPubMedGoogle Scholar
  • 18 Driot F, Vallee E. Prostaglandin metabolism and mechanism of action of ticlopidine. V. International Conference Prostaglandins. (Abstr.). Florence, May 18-21, 1982: 196
    PubMedGoogle Scholar
  • 19 Vincent JE, Zijlstra FJ, von de Veedonk MAM, Bonta IL. The effect of ticlopidine on the aggregation of rat blood platelets and on the formation of metabolites of arachidonic acid and 8, 11, 14 eicosatrienoic acid in rat platelets during aggregation and in the rat kidney. V. International Conference Prostaglandins. 197 (Abstr.). Florence, May 18-21, 1982
    PubMedGoogle Scholar